
An International Publisher for Academic and Scientific Journals
Author Login
Scholars Journal of Applied Medical Sciences | Volume-5 | Issue-12
Efficacy and safety of Different Statins among Newly Diagnosed Dyslipidemic Patients
Mohammad Al Mamun, Nilufar Fatema, Mohammod Zafor Iqbal Jamali, A. K. Al Miraj, Naveen sheikh, Fouzia sultana
Published: Dec. 30, 2017 |
332
314
DOI: 10.36347/sjams.2017.v05i12.080
Pages: 5232-5236
Downloads
Abstract
Background: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile. Methods: It is prospective real world observational study done at the Department of Cardiology BSMMU at the time July 2016 to August 2017 who were diagnosed as having dyslipidemia and indicated for statins but not already on statin were included in the study. Total of 120 patient’s data was available for analysis. Out of which 68 were in atorvastatin 10 mg group and 52 were in rosuvastatin 5 mg group. Baseline demographic and lipid profile was recorded. Lipid profile sample was taken after 12 hours of fasting. All patients were counselled for dietary control and exercise and were started on either atorvastatin 10 mg once daily or rosuvastatin 5 mg once daily according to physician’s discretion. Demographic profile and baseline lipid was recorded. Lipid profile was again recorded after 3 to 4 months of treatment. Result: Total of 120 patient’s data was available for analysis. Out of which 68 were in atorvastatin 10 mg group and 52 were in rosuvastatin 5 mg group. There was no significant difference in variables like gender, age, BMI, smoker, Diabetic and hypertensive among both the group. Total cholesterol decreased by 22 % (p = 0.002) in Atorvastatin group and by 22.6 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22 % (p = 0.004) in Atorvastatin group and 21.3% (p=0.005) in Rosuvastatin group. There was no significant difference between two gr